Topics

GSK Cuts Flu and Pneumonia Vaccines After Disappointing Data

20:00 EDT 1 May 2019 | BioSpace

In its announcement, GSK said the decision to cut the two programs were made following an analysis of available research results, including interim data from an ongoing Phase I study of the flu vaccine.

Original Article: GSK Cuts Flu and Pneumonia Vaccines After Disappointing Data

NEXT ARTICLE

More From BioPortfolio on "GSK Cuts Flu and Pneumonia Vaccines After Disappointing Data"

Quick Search

Relevant Topics

GlaxoSmithKline
GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Vaccine
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...